BioVector® C17 人鼻咽癌细胞系 / C17 Human Nasopharyngeal Carcinoma Cell Line

通用定义 / General Definition:BioVector® C17 是一种重要的人类鼻咽癌 (Nasopharyngeal Carcinoma, NPC) 细胞系。与许多其他在培养过程中丢失病毒基因组的 NPC 细胞系不同，C17 通常被认为是一个能够较好保留原始肿瘤生物学特征的模型。该细胞系广泛用于研究鼻咽癌的发生机制、上皮-间充质转化 (EMT) 过程、肿瘤血管生成以及对放化疗的敏感性。由于鼻咽癌在解剖学上的特殊性及其与 EB 病毒 (EBV) 的复杂关系，C17 提供了研究该特定恶性肿瘤的有力体外平台。

BioVector® C17 is a significant Human Nasopharyngeal Carcinoma (NPC) cell line. Unlike many other NPC lines that may lose their viral genome or undergo significant phenotypic shifts during prolonged culture, C17 is recognized as a model that effectively retains many original biological characteristics of the primary tumor. It is widely used to study the pathogenesis of NPC, Epithelial-Mesenchymal Transition (EMT), tumor angiogenesis, and sensitivity to radiotherapy and chemotherapy. Due to the unique anatomical site of NPC and its complex association with Epstein-Barr Virus (EBV), C17 provides a robust in vitro platform for investigating this specific malignancy.

BioVector® C17 技术说明书 (Technical Datasheet)

中文版说明书

1. 产品基本信息

• 产品名称： BioVector® C17 人鼻咽癌细胞

• 组织来源： 鼻咽 (Nasopharynx)

• 生长特性： 贴壁生长

• 细胞形态： 上皮样 (Epithelial-like)，呈多角形或铺路石状排列

2. 培养条件

• 基础培养基： BioVector® RPMI-1640 或 DMEM 培养基

• 血清添加： 10% BioVector® 优质胎牛血清 (FBS)

• 培养环境： 37 摄氏度，5% CO2，饱和湿度

• 传代比例： 1:3 至 1:4；建议在细胞汇合度达到 80% 至 90% 时进行传代。

3. 细胞应用

• 药物筛选： 评估新型靶向药物或免疫调节剂对鼻咽癌细胞的杀伤效果。

• 转移机制： 通过 Transwell 实验研究 NPC 细胞的迁移和侵袭能力。

• 放射生物学： 研究 C17 细胞对 X 射线或伽马射线照射的反应及其修复机制。

4. 注意事项

• 细胞交叉污染： 历史上部分 NPC 细胞系曾出现过被 HeLa 细胞污染的情况，BioVector® 建议对 C17 定期进行 STR 鉴定以确保其纯度。

• 操作规范： 尽管部分 NPC 细胞系不携带完整的 EBV，但处理人源肿瘤细胞时仍需遵循生物安全二级 (BSL-2) 标准。

English Datasheet

1. General Product Information

• Product Name: BioVector® C17 Human Nasopharyngeal Carcinoma Cell Line

• Tissue Source: Nasopharynx

• Growth Properties: Adherent

• Morphology: Epithelial-like, appearing polygonal or arranged in cobblestone patterns

2. Culture Conditions

• Basal Medium: BioVector® RPMI-1640 or DMEM Medium

• Serum Supplement: 10% BioVector® Fetal Bovine Serum (FBS)

• Incubation: 37 degrees Celsius, 5% CO2, Saturated Humidity

• Subculturing: 1:3 to 1:4 ratio; subculture when cells reach 80% to 90% confluence.

3. Applications

• Drug Screening: Evaluating the cytotoxic effects of novel targeted therapies or immunomodulators on NPC cells.

• Metastasis Mechanisms: Utilizing Transwell assays to investigate the migration and invasive potential of the cells.

• Radiobiology: Studying the response of C17 cells to X-ray or gamma radiation and their subsequent DNA repair mechanisms.

4. Key Usage Notes

• Authentication: Historically, some NPC cell lines have been found to be cross-contaminated with HeLa cells. BioVector® strongly recommends periodic STR (Short Tandem Repeat) profiling to verify the identity and purity of the C17 line.

• Standard Precautions: Even if certain NPC sub-lines do not harbor the full EBV genome, all human tumor cell lines must be handled according to Biosafety Level 2 (BSL-2) guidelines.

Note: For optimal cell recovery and growth, BioVector® recommends using pre-warmed media and avoiding prolonged exposure to trypsin during dissociation. Consistent use of BioVector® validated FBS ensures the stability of the epithelial phenotype.

Supplier生产厂家: BioVector NTCC典型培养物保藏中心

E-mail: BioVector@163.com

http://www.biovector.net